<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32943739</PMID><DateCompleted><Year>2020</Year><Month>12</Month><Day>04</Day></DateCompleted><DateRevised><Year>2021</Year><Month>09</Month><Day>17</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><Issue>1</Issue><PubDate><Year>2020</Year><Month>Sep</Month><Day>17</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>Elevated acute phase proteins reflect peripheral inflammation and disease severity in patients with amyotrophic lateral sclerosis.</ArticleTitle><Pagination><StartPage>15295</StartPage><MedlinePgn>15295</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">15295</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-020-72247-5</ELocationID><Abstract><AbstractText>Amyotrophic lateral sclerosis (ALS) is a multifactorial, multisystem pro-inflammatory neuromuscular disorder compromising muscle function resulting in death. Neuroinflammation is known to accelerate disease progression and accentuate disease severity, but peripheral inflammatory processes are not well documented. Acute phase proteins (APPs), plasma proteins synthesized in the liver, are increased in response to inflammation. The objective of this study was to provide evidence for peripheral inflammation by examining levels of APPs, and their contribution to disease burden and progression rates. Levels of APPs, including soluble CD14 (sCD14), lipopolysaccharide binding protein (LBP), and C-reactive protein (CRP), were elevated in sera, and correlated positively with increased disease burden and faster progression. sCD14 was also elevated in patients' CSF and urine. After a 3&#xa0;year follow-up, 72% of the patients with sCD14 levels above the receiver operating characteristics cutoff were deceased whereas only 28% below the cutoff were deceased. Furthermore, disease onset sites were associated with disease progression rates and APP levels. These APPs were not elevated in sera of patients with Alzheimer's Disease, frontotemporal dementia, or Parkinson's Disease. These collective APPs accurately reflect disease burden, progression rates, and survival times, reinforcing the concept of ALS as a disorder with extensive systemic pro-inflammatory responses.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Beers</LastName><ForeName>David R</ForeName><Initials>DR</Initials><AffiliationInfo><Affiliation>Peggy and Gary Edwards ALS Laboratory, Department of Neurology, Houston Methodist Neurological Institute, Houston Methodist Research Institute, Houston Methodist Hospital, Houston, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Zhao</LastName><ForeName>Weihua</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Peggy and Gary Edwards ALS Laboratory, Department of Neurology, Houston Methodist Neurological Institute, Houston Methodist Research Institute, Houston Methodist Hospital, Houston, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Neal</LastName><ForeName>Daniel W</ForeName><Initials>DW</Initials><AffiliationInfo><Affiliation>Department of Surgery, University of Florida College of Medicine, Gainesville, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thonhoff</LastName><ForeName>Jason R</ForeName><Initials>JR</Initials><AffiliationInfo><Affiliation>Peggy and Gary Edwards ALS Laboratory, Department of Neurology, Houston Methodist Neurological Institute, Houston Methodist Research Institute, Houston Methodist Hospital, Houston, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thome</LastName><ForeName>Aaron D</ForeName><Initials>AD</Initials><AffiliationInfo><Affiliation>Peggy and Gary Edwards ALS Laboratory, Department of Neurology, Houston Methodist Neurological Institute, Houston Methodist Research Institute, Houston Methodist Hospital, Houston, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Faridar</LastName><ForeName>Alireza</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Peggy and Gary Edwards ALS Laboratory, Department of Neurology, Houston Methodist Neurological Institute, Houston Methodist Research Institute, Houston Methodist Hospital, Houston, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wen</LastName><ForeName>Shixiang</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Peggy and Gary Edwards ALS Laboratory, Department of Neurology, Houston Methodist Neurological Institute, Houston Methodist Research Institute, Houston Methodist Hospital, Houston, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Jinghong</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Peggy and Gary Edwards ALS Laboratory, Department of Neurology, Houston Methodist Neurological Institute, Houston Methodist Research Institute, Houston Methodist Hospital, Houston, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Appel</LastName><ForeName>Stanley H</ForeName><Initials>SH</Initials><AffiliationInfo><Affiliation>Peggy and Gary Edwards ALS Laboratory, Department of Neurology, Houston Methodist Neurological Institute, Houston Methodist Research Institute, Houston Methodist Hospital, Houston, TX, USA. sappel@houstonmethodist.org.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Houston Methodist Neurological Institute, 6560 Fannin Street, Suite ST-802, Houston, TX, 77030, USA. sappel@houstonmethodist.org.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>09</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000209">Acute-Phase Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018950">Lipopolysaccharide Receptors</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000209" MajorTopicYN="N">Acute-Phase Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018950" MajorTopicYN="N">Lipopolysaccharide Receptors</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009000" MajorTopicYN="N">Monocytes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012372" MajorTopicYN="N">ROC Curve</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>DRB and SHA declare a conflict of interest with Implicit Bioscience. The other authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>5</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>8</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>9</Month><Day>18</Day><Hour>5</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>9</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32943739</ArticleId><ArticleId IdType="pmc">PMC7499429</ArticleId><ArticleId IdType="doi">10.1038/s41598-020-72247-5</ArticleId><ArticleId IdType="pii">10.1038/s41598-020-72247-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Brown RH, Al-Chalabi A. Amyotrophic lateral sclerosis. N. Engl. J. Med. 2017;377:162&#x2013;172.</Citation><ArticleIdList><ArticleId IdType="pubmed">28700839</ArticleId></ArticleIdList></Reference><Reference><Citation>Beers DR, Appel SH. Immune dysregulation in amyotrophic lateral sclerosis: Mechanisms and emerging therapies. Lancet Neurol. 2019;18:211&#x2013;220.</Citation><ArticleIdList><ArticleId IdType="pubmed">30663610</ArticleId></ArticleIdList></Reference><Reference><Citation>Henkel JS, et al. Regulatory T-lymphocytes mediate amyotrophic lateral sclerosis progression and survival. EMBO Mol. Med. 2013;5:64&#x2013;79.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3569654</ArticleId><ArticleId IdType="pubmed">23143995</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu CH, et al. Systemic inflammatory response and neuromuscular involvement in amyotrophic lateral sclerosis. Neurol. Neuroimmunol. Neuroinflamm. 2016;3:e244.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4897985</ArticleId><ArticleId IdType="pubmed">27308305</ArticleId></ArticleIdList></Reference><Reference><Citation>Beers DR, et al. ALS patients' regulatory T lymphocytes are dysfunctional, and correlate with disease progression rate and severity. JCI Insight. 2017;2:e89530.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5333967</ArticleId><ArticleId IdType="pubmed">28289705</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao W, et al. Characterization of gene expression phenotype in amyotrophic lateral sclerosis monocytes. JAMA Neurol. 2017;74:677&#x2013;685.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5822209</ArticleId><ArticleId IdType="pubmed">28437540</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheean RK, et al. Association of regulatory T-cell expansion with progression of amyotrophic lateral sclerosis: A study of humans and a transgenic mouse model. JAMA Neurol. 2018;75:681&#x2013;689.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5885208</ArticleId><ArticleId IdType="pubmed">29507931</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu Y, et al. Increased peripheral blood inflammatory cytokine levels in amyotrophic lateral sclerosis: A meta-analysis study. Sci. Rep. 2017;7:9094.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5567306</ArticleId><ArticleId IdType="pubmed">28831083</ArticleId></ArticleIdList></Reference><Reference><Citation>Murdock BJ, et al. Correlation of peripheral immunity with rapid amyotrophic lateral sclerosis progression. JAMA Neurol. 2017;74:1446&#x2013;1454.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5822195</ArticleId><ArticleId IdType="pubmed">28973548</ArticleId></ArticleIdList></Reference><Reference><Citation>Gustafson MP, et al. Comprehensive immune profiling reveals substantial immune system alterations in a subset of patients with amyotrophic lateral sclerosis. PLoS ONE. 2017;12:e0182002.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5526569</ArticleId><ArticleId IdType="pubmed">28742871</ArticleId></ArticleIdList></Reference><Reference><Citation>Keizman D, et al. Low-grade systemic inflammation in patients with amyotrophic lateral sclerosis. Acta Neurol. Scand. 2009;119:383&#x2013;389.</Citation><ArticleIdList><ArticleId IdType="pubmed">18976328</ArticleId></ArticleIdList></Reference><Reference><Citation>Gruys E, Toussaint MJ, Niewold TA, Koopmans SJ. Acute phase reaction and acute phase proteins. J. Zhejiang Univ. Sci. B. 2005;6:1045&#x2013;1056.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1390650</ArticleId><ArticleId IdType="pubmed">16252337</ArticleId></ArticleIdList></Reference><Reference><Citation>Vreugdenhil AC, Dentener MA, Snoek AM, Greve JW, Buurman WA. Lipopolysaccharide binding protein and serum amyloid A secretion by human intestinal epithelial cells during the acute phase response. J. Immunol. 1999;163:2792&#x2013;2798.</Citation><ArticleIdList><ArticleId IdType="pubmed">10453023</ArticleId></ArticleIdList></Reference><Reference><Citation>Bas S, Gauthier BR, Spenato U, Stingelin S, Gabay C. CD14 is an acute-phase protein. J. Immunol. 2004;172:4470&#x2013;4479.</Citation><ArticleIdList><ArticleId IdType="pubmed">15034063</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiner AP, et al. Soluble CD14: Genomewide association analysis and relationship to cardiovascular risk and mortality in older adults. Arterioscler. Thromb. Vasc. Biol. 2013;33:158&#x2013;164.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3826541</ArticleId><ArticleId IdType="pubmed">23162014</ArticleId></ArticleIdList></Reference><Reference><Citation>Lunetta C, et al. Serum C-reactive protein as a prognostic biomarker in amyotrophic lateral sclerosis. JAMA Neurol. 2017;74:660&#x2013;667.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5822215</ArticleId><ArticleId IdType="pubmed">28384752</ArticleId></ArticleIdList></Reference><Reference><Citation>Bazil V, Strominger J. Shedding as a mechanism of down-modulation of CD14 on stimulated human monocytes. J. Immunol. 1991;147:1567&#x2013;1574.</Citation><ArticleIdList><ArticleId IdType="pubmed">1880416</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamasaki H, Nishi H, Nagake Y, Mino Y, Makino H. Changes in CD14 expression on monocytes and changes in serum soluble CD14 level during hemodialysis. Clin. Exp. Nephrol. 2000;4:58&#x2013;62.</Citation></Reference><Reference><Citation>Tang K, et al. Elevated plasma soluble CD14 levels correlate with the monocyte response status during Hantaan virus infection in humans. Viral Immunol. 2015;28:442&#x2013;447.</Citation><ArticleIdList><ArticleId IdType="pubmed">26196589</ArticleId></ArticleIdList></Reference><Reference><Citation>Shive CL, Jiang W, Anthony DD, Lederman MM. Soluble CD14 is a nonspecific marker of monocyte activation. AIDS. 2015;29:1263&#x2013;1265.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4452959</ArticleId><ArticleId IdType="pubmed">26035325</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi I, et al. Identification of plasma microRNAs as a biomarker of sporadic amyotrophic lateral sclerosis. Mol. Brain. 2015;8:67.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4619470</ArticleId><ArticleId IdType="pubmed">26497046</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo J, Yang X, Gao L, Zang D. Evaluating the levels of CSF and serum factors in ALS. Brain Behav. 2017;7:e00637.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5346523</ArticleId><ArticleId IdType="pubmed">28293476</ArticleId></ArticleIdList></Reference><Reference><Citation>Haverkamp LJ, Appel V, Appel SH. Natural history of amyotrophic lateral sclerosis in a database population. Validation of a scoring system and a model for survival prediction. Brain. 1995;118:707&#x2013;719.</Citation><ArticleIdList><ArticleId IdType="pubmed">7600088</ArticleId></ArticleIdList></Reference><Reference><Citation>Voustianiouk A, et al. ALSFRS and Appel ALS scores: Discordance with disease progression. Muscle Nerve. 2008;37:668&#x2013;672.</Citation><ArticleIdList><ArticleId IdType="pubmed">18288708</ArticleId></ArticleIdList></Reference><Reference><Citation>Arias MA, et al. Cutting edge: Human B cell function is regulated by interaction with soluble CD14: Opposite effects on IgG1 and IgE production. J. Immunol. 2000;164:3480&#x2013;3486.</Citation><ArticleIdList><ArticleId IdType="pubmed">10725700</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderson AC, et al. Promotion of tissue inflammation by the immune receptor Tim-3 expressed on innate immune cells. Science. 2017;318:1141&#x2013;1143.</Citation><ArticleIdList><ArticleId IdType="pubmed">18006747</ArticleId></ArticleIdList></Reference><Reference><Citation>Han G, Chen G, Shen B, Li Y. Tim-3: An activation marker and activation limiter of innate immune cells. Front. Immunol. 2013;4:449.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3857553</ArticleId><ArticleId IdType="pubmed">24339828</ArticleId></ArticleIdList></Reference><Reference><Citation>Beers DR, Henkel JS, Zhao W, Wang J, Appel SH. CD4+ T cells support glial neuroprotection, slow disease progression, and modify glial morphology in an animal model of inherited ALS. Proc. Natl. Acad. Sci. U.S.A. 2008;105:15558&#x2013;15563.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2547419</ArticleId><ArticleId IdType="pubmed">18809917</ArticleId></ArticleIdList></Reference><Reference><Citation>Beers DR, et al. Neuroinflammation modulates distinct regional and temporal clinical responses in ALS mice. Brain Behav. Immunol. 2011;25:1025&#x2013;1035.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3096756</ArticleId><ArticleId IdType="pubmed">21176785</ArticleId></ArticleIdList></Reference><Reference><Citation>Appel SH, Beers DR, Henkel JS. T cell-microglial dialogue in Parkinson's disease and amyotrophic lateral sclerosis: Are we listening? Trends Immunol. 2010;31:7&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4126423</ArticleId><ArticleId IdType="pubmed">19879804</ArticleId></ArticleIdList></Reference><Reference><Citation>Appel SH, Zhao W, Beers DR, Henkel JS. The microglial-motoneuron dialogue in ALS. Acta Myol. 2011;30:4&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3185827</ArticleId><ArticleId IdType="pubmed">21842586</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakano Y, Hirayama K, Terao K. Hepatic ultrastructural changes and liver dysfunction in amyotrophic lateral sclerosis. Arch. Neurol. 1987;44:103&#x2013;106.</Citation><ArticleIdList><ArticleId IdType="pubmed">3800708</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee SH, Yang EJ. Relationship between liver pathology and disease progression in a murine model of amyotrophic lateral sclerosis. Neurodegener. Dis. 2018;18:200&#x2013;207.</Citation><ArticleIdList><ArticleId IdType="pubmed">30130789</ArticleId></ArticleIdList></Reference><Reference><Citation>Sampson TR, et al. Gut microbiota regulate motor deficits and neuroinflammation in a model of Parkinson&#x2019;s disease. Cell. 2016;167:1469&#x2013;1480.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5718049</ArticleId><ArticleId IdType="pubmed">27912057</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharon G, et al. Human gut microbiota from autism spectrum disorder promote behavioral symptoms in mice. Cell. 2019;177:1600&#x2013;1618.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6993574</ArticleId><ArticleId IdType="pubmed">31150625</ArticleId></ArticleIdList></Reference><Reference><Citation>Blacher E, et al. Potential roles of gut microbiome and metabolites in modulating ALS in mice. Nature. 2019;572:474&#x2013;480.</Citation><ArticleIdList><ArticleId IdType="pubmed">31330533</ArticleId></ArticleIdList></Reference><Reference><Citation>Kundu P, Blacher E, Elinav E, Pettersson S. Our gut microbiome: The evolving inner self. Cell. 2017;171:1481&#x2013;1493.</Citation><ArticleIdList><ArticleId IdType="pubmed">29245010</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim S, et al. Transneuronal propagation of pathologic &#x3b1;-synuclein from the gut to the brain models Parkinson's Disease. Neuron. 2019;103:627&#x2013;641.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6706297</ArticleId><ArticleId IdType="pubmed">31255487</ArticleId></ArticleIdList></Reference><Reference><Citation>Marcos V, et al. Expression, regulation and clinical significance of soluble and membrane CD14 receptors in pediatric inflammatory lung diseases. Respir. Res. 2010;11:32.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2845564</ArticleId><ArticleId IdType="pubmed">20302606</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan Z, Zhou L, Hetherington CJ, Zhang DE. Hepatocytes contribute to soluble CD14 production, and CD14 expression is differentially regulated in hepatocytes and monocytes. J. Biol. Chem. 2000;75:36430&#x2013;36435.</Citation><ArticleIdList><ArticleId IdType="pubmed">10960472</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang R, et al. Circulating endotoxin and systemic immune activation in sporadic amyotrophic lateral sclerosis (sALS) J. Neuroimmunol. 2009;206:121&#x2013;124.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2995297</ArticleId><ArticleId IdType="pubmed">19013651</ArticleId></ArticleIdList></Reference><Reference><Citation>Wuthrich B, Kagi MK, Joller-Jemelka H. Soluble CD14 but not interleukin-6 is a new marker for clinical activity in atopic dermatitis. Arch. Dermatol. Res. 1992;284:339.</Citation><ArticleIdList><ArticleId IdType="pubmed">1284103</ArticleId></ArticleIdList></Reference><Reference><Citation>Horneff G, Sack U, Kalden JR, Emmrich F, Burmester GR. Reduction of monocyte-macrophage activation markers upon anti-CD4 treatment: Decreased levels of IL-1, IL-6, neopterin and soluble CD14 in patients with rheumatoid arthritis. Clin. Exp. Immunol. 1993;91:207&#x2013;213.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1554673</ArticleId><ArticleId IdType="pubmed">7679058</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu S, et al. Pathological significance of elevated soluble CD14 production in rheumatoid arthritis: In the presence of soluble CD14, lipopolysaccharides at low concentrations activate RA synovial fibroblasts. Rheumatol. Int. 1998;17:237&#x2013;243.</Citation><ArticleIdList><ArticleId IdType="pubmed">9592864</ArticleId></ArticleIdList></Reference><Reference><Citation>Oesterreicher C, Pfeffel F, Petermann D, Muller C. Increased in vitro production and serum levels of the soluble lipopolysaccharide receptor sCD14 in liver disease. J. Hepatol. 1995;23:396&#x2013;402.</Citation><ArticleIdList><ArticleId IdType="pubmed">8655956</ArticleId></ArticleIdList></Reference><Reference><Citation>Takeshita S, et al. Increased levels of circulating soluble CD14 in Kawasaki disease. Clin. Exp. Immunol. 2000;119:376&#x2013;381.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1905502</ArticleId><ArticleId IdType="pubmed">10632678</ArticleId></ArticleIdList></Reference><Reference><Citation>Egerer K, et al. Increased serum soluble CD14, ICAM-1 and E-selectin correlate with disease activity and prognosis in systemic lupus erythematosus. Lupus. 2000;9:614&#x2013;621.</Citation><ArticleIdList><ArticleId IdType="pubmed">11035437</ArticleId></ArticleIdList></Reference><Reference><Citation>Colonna M, Wang Y. TREM2 variants: New keys to decipher Alzheimer disease pathogenesis. Nat. Rev. Neurosci. 2016;17:201&#x2013;207.</Citation><ArticleIdList><ArticleId IdType="pubmed">26911435</ArticleId></ArticleIdList></Reference><Reference><Citation>Hafer-Macko CE, et al. Immune attack on the Schwann cell surface in acute inflammatory demyelinating polyneuropathy. Ann. Neurol. 1996;39:625&#x2013;635.</Citation><ArticleIdList><ArticleId IdType="pubmed">8619548</ArticleId></ArticleIdList></Reference><Reference><Citation>S&#xfc;ssmuth SD, et al. CSF glial markers correlate with survival in amyotrophic lateral sclerosis. Neurology. 2010;74:982&#x2013;987.</Citation><ArticleIdList><ArticleId IdType="pubmed">20308682</ArticleId></ArticleIdList></Reference><Reference><Citation>Papanas N, et al. Peripheral neuropathy is associated with increased serum levels of uric acid in type 2 diabetes mellitus. Angiology. 2011;62:291&#x2013;295.</Citation><ArticleIdList><ArticleId IdType="pubmed">21306998</ArticleId></ArticleIdList></Reference><Reference><Citation>Cruz-Guzm&#xe1;n Odel R, Rodr&#xed;guez-Cruz M, Escobar Cedillo RE. Systemic inflammation in Duchenne muscular dystrophy: Association with muscle function and nutritional status. Biomed. Res. Int. 2015 doi: 10.1155/2015/891972.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2015/891972</ArticleId><ArticleId IdType="pmc">PMC4561314</ArticleId><ArticleId IdType="pubmed">26380303</ArticleId></ArticleIdList></Reference><Reference><Citation>Kianmehr N, Haghighi A, Moghaddasi M, Mofidi M. Chronic inflammatory demyelinating polyneuropathy (CIDP) as a first presentation of systemic lupus erythematosus. Rheumatol. Res. 2017;2:75&#x2013;78.</Citation></Reference><Reference><Citation>Tortarolo M, et al. Amyotrophic lateral sclerosis, a multisystem pathology: Insights into the role of TNF&#x3b1;. Mediat. Inflamm. 2017;2017:2985051.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5610855</ArticleId><ArticleId IdType="pubmed">29081600</ArticleId></ArticleIdList></Reference><Reference><Citation>Janciauskiene, S., Welte, T., Mahadeva, R. Acute phase proteins: Structure and function relationship. in Acute Phase Proteins: Regulation and Functions of Acute Phase Proteins. Chapter 2 (2011).</Citation></Reference><Reference><Citation>Ono S, Hu J, Shimizu N, Imai T, Nakagawa H. Increased interleukin-6 of skin and serum in amyotrophic lateral sclerosis. J. Neurol. Sci. 2001;187:27&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">11440741</ArticleId></ArticleIdList></Reference><Reference><Citation>Babu GN, et al. Elevated inflammatory markers in a group of amyotrophic lateral sclerosis patients from northern India. Neurochem. Res. 2008;33:1145&#x2013;1149.</Citation><ArticleIdList><ArticleId IdType="pubmed">18246426</ArticleId></ArticleIdList></Reference><Reference><Citation>Cereda C, et al. TNF and sTNFR1/2 plasma levels in ALS patients. J. Neuroimmunol. 2008;194:123&#x2013;131.</Citation><ArticleIdList><ArticleId IdType="pubmed">18083240</ArticleId></ArticleIdList></Reference><Reference><Citation>Thonhoff JR, et al. Expanded autologous regulatory T-lymphocyte infusions in ALS: A phase I, first-in-human study. Neurol. Neuroimmunol. Neuroinflamm. 2018;5:e465.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5961523</ArticleId><ArticleId IdType="pubmed">29845093</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner MR, et al. Evidence of widespread cerebral microglial activation in amyotrophic lateral sclerosis: An [11C](R)-PK11195 positron emission tomography study. Neurobiol. Dis. 2004;5:601&#x2013;609.</Citation><ArticleIdList><ArticleId IdType="pubmed">15056468</ArticleId></ArticleIdList></Reference><Reference><Citation>Corcia P, et al. Molecular imaging of microglial activation in amyotrophic lateral sclerosis. PLoS ONE. 2012;7:e52941.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3534121</ArticleId><ArticleId IdType="pubmed">23300829</ArticleId></ArticleIdList></Reference><Reference><Citation>Brites D, Vaz AR. Microglia centered pathogenesis in ALS: Insights in cell interconnectivity. Front. Cell. Neurosci. 2014;8:117.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4033073</ArticleId><ArticleId IdType="pubmed">24904276</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>